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StreptozotocinLarge scale clinical trials have demonstrated that an intensive antihyperglycemic treatment in diabetes
mellitus (DM) in individuals reduces the incidence of micro- and macrovascular complications, e.g.
nephropathy, retinopathy, DM-accelerated atherosclerosis, myocardial infarction, or limb amputations.
Here, we investigated the effect of short- and long-term insulin administration on mitochondrial function in
peripheral tissues of streptozotocin (STZ)-induced hyperglycemic rats. In addition, the in vitro effect of
methylglyoxal (MG), advanced glycation end products (AGEs) and human diabetic plasma on mitochondrial
activity was investigated in skeletal muscle and liver mitochondria and in rat skin primary ﬁbroblasts.
Hyperglycemic STZ rats showed tissue-speciﬁc patterns of energy deﬁciency, evidenced by reduced activities
of complexes I, II and/or IV after 30 days of hyperglycemia in heart, skeletal muscle and liver; moreover,
cardiac tissue was found to be the most sensitive to the diabetic condition, since energy metabolism was
impaired after 10 days of the hyperglycemia. Insulin-induced tight glycemic control was effective in
protecting against the hyperglycemia-induced inhibition of mitochondrial enzyme activities. Furthermore,
the long-term hormone replacement (30 days) also increased these activities in kidney from STZ-treated
animals, where the hyperglycemic state did not modify the electron transport activity. Results from in vitro
experiments indicate that mitochondrial impairment could result from oxidative stress-induced accumula-
tion of MG and/or AGEs. Further investigations demonstrated that human plasma AGE accumulation elicits
reduced mitochondrial function in skin ﬁbroblast. These data suggest that persistent hyperglycemia results in
tissue-speciﬁc patterns of energy deﬁciency and that early and continuous insulin therapy is necessary to
maintain proper mitochondrial metabolism.ica e Estresse Oxidativo Centro
Catarina Florianópolis Brazil.
t authors.
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Diabetes mellitus (DM), a state of chronic hyperglycemia, is a
common disease and one of the leading causes of morbidity and
mortality in developed countries. DM currently affects more than
124 million individuals, and it is estimated that 300 million people
worldwide will suffer from the disease by 2025 [1].Chronic DM is characterized by the development of speciﬁc
microvasculature pathology in the retina, renal glomerulus and
peripheral nerves. As a consequence of these microvascular compli-
cations, DM is the leading cause of blindness, kidney failure and a
variety of debilitating neuropathies [2–5]. The microvascular dysfunc-
tions are also known to induce the development of DMmacrovascular
pathology [6], which is characterized by DM-accelerated atheroscle-
rosis, which in turn leads to increased risk of myocardial infarction,
stroke and limb amputations [7,8]. Although microvascular complica-
tions are responsible for signiﬁcant morbidity and premature
mortality, by far the greatest cause of death in people with diabetes
is cardiovascular disease [9,10]. Such macrovascular changes occur
much earlier in life than in the general population, and also present a
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among those aged less than 40 years [11,12].
Several large randomized controlled trials have conclusively
demonstrated that early intensive glycemic control decreases the
risk of diabetic microvascular complications [12–14]. Although the
Diabetes Control and Complications trial Research group (DCCT) showed
only a trend towards a lower risk for cardiovascular events
(macrovascular pathology), the almost 10 years post-DCCT follow-
up of the cohort showed a signiﬁcant reduction in the risk of nonfatal
myocardial infarction, stroke, or death from cardiovascular disease
[12,13]. Thus, these ﬁndings suggest that early metabolic control
would have beneﬁcial effects on the vasculature. This phenomenon
has been deﬁned as metabolic memory, an early imprinting in cells
arising from hyperglycemia, favoring the future development of
vascular complications. This hypothesis describes the observation that
prolonged, tight glycemic control during early (newly diagnosed to
ﬁve years post-diagnosis) but not later stages of DM would bring
about a sustained beneﬁt regarding micro- and macrovascular
endpoints [2,12,13].
On the other hand, persistent hyperglycemia appears to activate
four major pathways implicated in the pathogenesis of diabetes
complications, namely the hexosamine and polyol pathways, protein
kinase C isoforms, and formation of the reactive carbonyl compounds
methylglyoxal (MG) and glyoxal [15]. These carbonyl compounds
form covalent adducts with speciﬁc lysine and arginine residues in
proteins, leading to the formation of intracellular advanced glycation
end products (AGEs), which consequently will alter protein function.
MG is the major source of AGEs in hyperglycemia [16]. MG-derived
AGEs (MG-AGE), which are particularly abundant in vascular tissue,
are thought to contribute to the observed micro- and macrovasculo-
pathies in late complications of DM [17–22].
The observation that reduced rates of ATP synthesis in subjects
with a family history of type 2 DM occur before the onset of impaired
glucose tolerance indicates the signiﬁcance of mitochondrial dys-
function in the progression of the disease [23]. In this context,
experimental data have demonstrated that AGEs may initiate
pathologic processes by impairing mitochondrial function [24], by
inducing apoptosis [25–27] and by stimulating overproduction of
cytokines and reactive oxygen species (ROS) [28,29]. Therefore, in
order to better understand the effect of glycemic control on cellular
energy and oxidative metabolisms, here we investigated the effect of
short- and long-term insulin administration in skeletal and cardiac
muscles, kidneys and liver from streptozotocin-induced hyperglyce-
mic rats. In addition, the effect of MG, MG-AGE and human diabetic
plasma on mitochondrial function was investigated in skeletal muscle
and liver mitochondrial preparations and in skin primary ﬁbroblasts.
2. Material and methods
2.1. Human plasma samples
Plasma diabetic individuals with poor control of glycemia (range:
146–296 mg/dL; n=9), and non-diabetic healthy subjects (n=3), all
within the age range of 30–92 years, were included in this study.
Details of the study were submitted to and received the approval of
the Ethical Committee for Human Research (CEPSH/435/09) of the
Universidade Federal de Santa Catarina, Florianópolis— SC, Brazil. The
procedures were performed in accordance with The Code of Ethics of
theWorld Medical Association (Declaration of Helsinki). Additionally,
written informed consent was obtained from each participant prior to
the commencement of the study.
2.2. Animals and reagents
Male Wistar rats of 60 days of life (250–300 g) obtained from the
Central Animal House of the Centre for Biological Sciences, Universi-dade Federal de Santa Catarina, Florianópolis— SC, Brazil, were used in
the present investigation. The animals were maintained on a 12-h
light/dark cycle in a constant temperature room (22 °C±1 °C), with
free access towater and protein commercial chow (Nuvital-PR, Brazil),
except in the fasting periods previous to blood glucose measurements
(see below). In addition, neonatal rats were used for preparing skin
ﬁbroblast cultures. The experimental protocol was approved by the
Ethics Committee for Animal Research (PP00350/CEUA) of the
Universidade Federal de Santa Catarina, Florianópolis — SC, Brazil,
and was carried out in accordance with the European Communities
Council Directive of 24 November 1986 (86/609/EEC). All efforts were
made to minimize the number of animals used and their suffering.
All chemicals were of analytical grade and purchased from Sigma
(St. Louis, MO, USA), except Novolin®N insulin, which was purchased
from Novo Nordisk Laboratories (Princeton, NJ, USA) and fetal bovine
serum from Gibco® (Carlsbad, CA, USA). Commercial methylglyoxal
(40%V/V) was also purchased from Sigma. According to the manufac-
turer's information the compound is free of biological toxins and
chemically synthesized by acid hydrolysis of pyruvaldehyde dimethyl
acetal at 100 °C for 25 min.
2.3. Induction of hyperglycemia by streptozotocin (STZ) administration
(Scheme 1)
Hyperglycemia was induced by a single intraperitoneal injection of
55 mg/kg STZ, diluted in sodium–citrate buffer (pH 4.5), after a fasting
period of 14 h. Proper controls were run in parallel. STZ-treated rats
received 5% glucose solution instead of water during 24 h after STZ
administration in order to avoid death due to hypoglycemic shock.
Blood glucose concentrations were assessed four days after STZ
injection. Glycemia was measured by using a commercial glucometer
(Optium™Xceed, Abbott, USA). Animals with blood glucose levels
higher than 200 mg/dL (11 mmol/L) were included in the experiments.
Hyperglycemic animals were divided in two groups, the STZ group,
which remains hyperglycemic for 10 and 30 days, and the STZ+INS
group, which received 1.5 UI Novolin®N insulin twice a day in order to
normalize blood glucose levels, for 10 and 30 days. In order to assure the
insulin-induced tight control of glycemia, blood glucose levels were
measured each week. Animal body weight was followed daily.
2.4. Tissue preparation for biochemical analysis
Animals were killed by decapitation without anesthesia. The
skeletal and cardiac muscles, kidney and liver were rapidly dissected,
weighed and kept chilled until homogenization, which was per-
formed using a ground glass type Potter–Elvejhem homogenizer. The
maximum period between the tissue preparation and biochemical
analysis was always less than a week. Samples were kept at −86 °C
until biochemical determinations.
2.5. Tissue mitochondrial preparation for measuring the respiratory
chain complex activities
Mitochondria suspensions were prepared as previously described
by our group [30]. Brieﬂy, tissues were homogenized in 10 volumes of
4.4 mM potassium phosphate buffer pH 7.4, containing 0.3 M sucrose,
5 mM MOPS, 1 mM EGTA and 0.1% bovine serum albumin. The
homogenates were centrifuged at 3000×g for 10 min at 4 °C. The
pellet was discarded and the supernatants were centrifuged at
17,000×g for 10 min at 4 °C. The obtained pellet was dissolved in
the same buffer. For these tissues preparations an Eppendorf 5415 R
centrifuge (Eppendorf, Hamburg, Germany) was used.
In vitro experiments were also performed in mitochondrial
suspensions obtained from non-treated adult rat skeletal muscle
and liver. For this purpose, mitochondrial fractions were prepared
as described above and treated with crescent concentrations of
Scheme 1. Experimental design. Hiperglycemic conditions were induced by intraperitoneal administration of streptozotocin (STZ). The glycemic control was achieved by treating
with insulin (INS; 1.5 UI Novolin®N) twice a day.
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Proper controls were run in parallel.
2.6. Tissue preparation for immunohistochemical analysis
Rats were anesthetized intraperitoneally with chloral hydrate
(400 mg/kg) and transcardially perfuse with heparin (1000 U/mL) in
physiological saline (0.9% NaCl) followed by 4% paraformaldehyde in
physiological saline. Skeletal muscle was removed and post-ﬁxed
overnight in 4% paraformaldehyde. Afterwards, the muscle was
transversally sectioned, dehydrated in ethanol, embedded in parafﬁn,
and sectioned in 10 μm slices. The quenching of endogenous
peroxidase was carried out using 1.5% hydrogen peroxide in methanol
(v/v) for 20 min. A high temperature antigen retrieval was performed
by immersion of the slices in a water bath at 95–98 °C in 10 mM
trisodium citrate buffer pH 6.0, for 45 min. Immunohistochemistry
was performed to identify DNA oxidative damage in skeletal
muscle, using primary monoclonal antibody anti-8-hydroxy-2′-
deoxyguanosine (dilution: 1:50; JaICA®, Shizuoka, Japan) incubated
overnight at 4 °C in a humid chamber. After incubation, the sliceswere
washed twice in PBS and then incubated in a secondary antibody
Alexa Fluor 633 (dilution: 1:100; Invitrogen®, USA) during 3 h.
Finally, the slices were mounted in GelMount (Sigma®, St. Louis, MO,
USA) and were observed under a conventional ﬂuorescence micro-
scope (Zeiss standard ﬂuorescence microscope). A threshold for the
optical density that better discriminated staining from the back-
ground was obtained using the NIH ImageJ 1.36b imaging software
(NIH, Bethesda, MD, USA). For relative quantiﬁcation of immunoex-
pression, total pixel intensity was determined and data were
expressed as average of optical density (O.D.).
2.7. Primary skin ﬁbroblast cell culture
Rat dermal ﬁbroblasts were obtained from skin biopsy sampled
from the dorsal region of normal neonatal female rats (1 day of life) by
employing explant techniques [31]. The cells were growth in DMEM
supplemented with 10% fetal bovine serum, sterile antimycotic
solution 100×: penicillin 100 IU/mL, streptomycin 0.1 mg/mL and
amphotericin 0.25 μg/mL, D-glucose 5.5 mM, 2% glutamine, 0.22%
NaHCO3, and 0.47% HEPES in a 5% CO2 humidiﬁed atmosphere, at
37 °C.2.8. Cell treatment
Conﬂuent ﬁbroblasts cultures (70% of conﬂuence; passages 6–8)
were maintained 24 h in the growth medium containing 0.5% fetal
bovine serum for synchronization of cell cycle. Afterwards, cells were
treated withmethylglyoxal (MG) (30 and 300 μM), MG-BSA (0.01, 0.1
and 1 mg/mL) and human diabetic plasma (dilution 1:4), for 3 and/or
24 h at 37 °C.
2.9. Preparations of MG-BSA
BSA highly modiﬁed by MG (MG-BSAhigh) was obtained after
incubating 7.2 mg/mL BSA with 100 mM MG in 100 mM sodium
phosphate buffer, pH 7.4 at 37 °C for 50 h, in sterile conditions
(solutions were ﬁltered by using 0.22 μm ﬁlters). The solution was
then dialyzed against 30 mM ammonium bicarbonate buffer, pH 7.9 at
4 °C. MG-BSA derivatives under less severe conditions were also
prepared by exposing BSA solution to 1 mM MG (MG-BSAlow) [32].
2.10. Characterization of BSA derivatives after MG exposure: measurement
of protein non-oxidized amino acids, Maillard compounds, protein
carbonylation and total protein quantiﬁcation by the Lowry method
The modiﬁcation of amino acid residues induced by MG exposure
was investigated by analyzing the reaction of TNBS (2,4,6-trinitro-
benzenesulfonic acid) with the non-oxidized amino acid present in
MG-BSAlow and MG-BSAhigh preparations [33].
In addition, the formation of Maillard compounds (measurement
of AGE formation) was identiﬁed as previously described [34].
The ﬂuorescence detection was performed at λex=370 nm and
λem=440 nm by using a Tecan GmbH M200 ﬂuorescence spectro-
photometer (Tecan, Grödig/Salzburg, Austria).
Protein carbonyl content determination (marker of protein
oxidative damage) was measured spectrophotometrically [35]. The
results were calculated as nmol of carbonyl groups/mg protein using
the extinction coefﬁcient of 22,000 106 nmol/mL for aliphatic
hydrazones.
Protein content in BSA preparations, as well as, in the animal
samples, was determined by the method of Lowry using BSA as the
standard [36]. This characterization is presented in Fig. 4A in the
Results section of this paper.
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Plasma samples were diluted and tested for Maillard compounds
as previously described [34]. The ﬂuorescence detectionwas performed
at λex=370 nm and λem=440 nm by using a Tecan GmbH M200
ﬂuorescence spectrophotometer (Tecan, Grödig/Salzburg, Austria). The
samples were previously assessed for glucose and protein concentra-
tions through the glucose–oxidase and Lowry [36] method,
respectively.
2.12. Measurement of mitochondrial function
Mitochondrial function of skin ﬁbroblasts was assessed by following
the MTT (3-[4,5 dimethylthiazol-2-y1]-2,5-diphenyltetrazolic bro-
mide) reduction. Active mitochondrial dehydrogenases cleavage and
reduce the soluble yellow MTT dye into the insoluble purple formazan
[37]. Cells were incubated with MG (30 and 300 μM), MG-BSAlow and
MG-BSAhigh (0.01, 0.1 and 1 mg/mL), and diluted human plasma (1:4)
for 3 and/or 24 h at 37 °C. At the end of the incubation period, MTT test
were performed. The formazan formation was spectrophotometrically
assayed at 570 nm and 630 nm, and the net ΔA(570–630) was taken as an
index of mitochondrial function. Results are indicated as percentage of
controls, to which 100% activity was attributed.
2.13. ROS production determination
Intracellular ROSproductionwasdetectedusing the non-ﬂuorescent
cell permeating compound, 2′,7′-dichloroﬂuorescein diacetate (DCFH-
DA) in treated skin ﬁbroblasts (see above). DCFH-DA is hydrolyzed by
intracellular esterases to DCFH, which is trapped within the cell. This
non-ﬂuorescent molecule is then oxidized to the ﬂuorescent dichloro-
ﬂuorescein (DCF) by cellular oxidants. MG and MG-BSA-exposed
ﬁbroblasts were treated with 10 μM DCFH-DA for 30 min at 37 °C.
Afterwards, the cells were scraped into PBS with 0.2% Triton X-100.
The ﬂuorescence was measured with excitation at 485 nm and
emission at 520 nm. Calibration curve was performed with standard
DCF (0–500 μM)and the level of ROSproductionwas calculated as nmol
DCF formed/mg protein and expressed as percentage of controls.
2.14. Measurement of the respiratory chain enzyme activities
Complex I activity was measured by the rate of NADH-dependent
ferricyanide reduction at 420 nm (1 mM− 1 .cm−1) as previously
described [38]. The activity of succinate-2,6-dichloroindophenol
(DCIP)-oxidoreductase (complex II) was determined according to the
method of Fischer et al. [39], and complex I–CoQ-III activity (NADH:
cytochrome C oxidoreductase) was assayed according to the method
described by Schapira et al. [40]. The activity of cytochrome C oxidase
(complex IV) was assessed according to Rustin et al. [41]. The methods
described tomeasure these activitieswere slightlymodiﬁed, as detailed
in a previous report [30]. The activities of the respiratory chain
complexes were calculated as μmol or nmol .min−1 .mg protein−1. The
enzyme activities were measured using a Varian Cary 50 spectropho-
tometer with temperature control (Varian Inc., Palo Alto, CA, USA).
2.15. Mitochondrial oxygen consumption
Oxygen consumption was determined in 24 h MG-BSA-treated
skin ﬁbroblast at 37 °C. Non-permeabilized skin ﬁbroblasts were
suspended in 4.4 mM potassium phosphate buffer pH 7.4, containing
0.3 M sucrose, 5 mM MOPS, 1 mM EGTA and 0.1% bovine serum
albumin at a cell concentration of 500,000 cells/mL. Respiration was
measured at 37 °C by high-resolution respirometry using the
Oroboros® oxygraph with chamber volumes set at 2 mL [42]. DatLab
software (Oroboros Instruments, Innsbruck, Austria) was used for
data acquisition (1 or 2 s time intervals) and analysis. The experi-mental regime was started with routine respiration, which is deﬁned
as respiration without additional substrates or effectors. After
observing steady-state respiratory ﬂux in the time interval between
15 and 30 min, the ATP synthase activity was inhibited with
oligomycin (1 μg/mL), followed by uncoupling of oxidative phosphor-
ylation by stepwise titration of FCCP (carbonyl cyanide p-triﬂuor-
omethoxyphenylhydrazone) up to optimum FCCP concentrations of
5.6 μM (80% of maximal mitochondrial electron transfer activity). A
typical titration curve is shown in Fig. 6B. Finally, respiration was
inhibited by sequential addition of rotenone (0.5 μM; to test for the
effect of inhibiting complex I activity) and antimycin A (2.5 μM;
inhibiting complex III).
2.16. Protein determination
Sample protein content was determined by the method of Lowry
using bovine serum albumin as the standard [36].
2.17. Statistical analysis
Results are presented as mean±standard deviation. Percentages
of rat weight gain (initial body weight was considered as 100%) data
were analyzed by using two-way ANOVA for repeated measures. Data
from animal biochemical determinations were analyzed using one-
way ANOVA followed by the post hoc Duncan multiple range test
when F was signiﬁcant. Only signiﬁcant F values were given in the
text. For analysis of dose-dependent effects, linear regression was
used. Differences between the groups were rated signiﬁcant at
P≤0.05. Data from human sample determinations were analyzed
using Student t test for unpaired samples. Statistics were performed
using SPSS® (Statistical Package for the Social Sciences software;
version 16.0 for Windows). All graphs were performed by using
GraphPad Prism 5®.
3. Results
3.1. Effect of 10 and 30 days of INS administration in body weight (BW)
gain and blood glucose concentrations in adult streptozotocin
(STZ)-administered Wistar rats
Fig. 1A shows the effect of INS administration in body weight (BW)
gain in adult STZ-administered Wistar rats. STZ treatment caused a
signiﬁcant reduction in the BW gain (starting after six days with 9.5%
of reduction and reaching 30% of reduction at the end of the
treatment), when comparing to controls. On the other side, INS
treatment avoided the loss of weight induced by STZ and after twenty-
four days of treatment the gain in the BW was increased in these
animals respective to controls (8.5% of increment at day 24 and 12.5%
of increment at day 30) (two-way ANOVA for repeated measure
analysis showed signiﬁcant effects between groups: Control, STZ and
(STZ+INS) [F=414.27; Pb0.001] and days of treatment— 30 days —
[F=8.91; Pb0.001]; interaction was observed between groups and
days of treatment [F=4.11; Pb0.001]; n=4–5 per group). Fig. 1B
shows that INS treatment was adequate to control blood glucose
levels both, after 10 and 30 days of STZ administration (protocol
for 10 days: at day 7=[F(2,12)=70.16; Pb0.001], at day 10=[F(2,9)=
398.82; Pb0.001], protocol for 30 days: at day 7=[F(2,26)=37.72;
Pb0.001], at day 15=[F(2,16)=153.20; Pb0.001], at day 30=
[F(2,19)=786.49; Pb0.001]).
3.2. Early and late effects of INS administration in mitochondrial complex
activities in peripheral tissues from adult STZ-administered Wistar rats
Fig. 2A, B and C shows the effect of INS administration on the
enzymatic activities of the respiratory complexes in mitochondrial
suspensions obtained from skeletal and cardiac muscles, kidney and
Fig. 1. Effect of 10 and 30 days of insulin (INS; 1.5 UI Novolin®N insulin twice/day) administration in body weight gain (BW) (A) and blood glucose concentrations in adult
streptozotocin (STZ)-administered Wistar rats (B). Data represent mean±standard deviation (5 to 9 animals/group). BW signiﬁcant differences between controls and STZ animals
started on day 6 (*), between STZ and STZ+INS animals on day 5 (#) and between controls and STZ+INS rats on day 24 (&) (two-way ANOVA for repeated measures). Glycemia
was controlled with 1.5 UI Novolin®N insulin twice a day andmeasure at days 7 and 10 for 10 day-hyperglycemic treatment and at days 7, 15 and 30 for 30 day- treatment. *Pb0.05;
*** Pb0.001, compared to the control group. ###Pb0.001, compared to the STZ group (one-way ANOVA followed by the Duncan multiple range test).
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long-term hyperglycemic condition (30 days) provoked a signiﬁcant
inhibition of the activities of the mitochondrial complexes I, II and IV,
(up to 22%, 43% and 36%, respectively) in skeletalmuscle, an effect that
was prevented by the daily administration of INS (complex I: [F(2,20)=
13.96; Pb0.001]; complex II: [F(2,20)=6.01; Pb0.01]; complex IV:
[F(2,6)=5.61; Pb0.05]). Similarly, cardiac muscle showed a reduction
in these complex activities after 30 days of treatment (up to 35%, 45%
and 34%, respectively) (complex I: [F(2,16)=40.77; Pb0.001]; complex
II: [F(2,19)=9.77; Pb0.001]; complex IV: [F(2,6)=7.26; Pb0.05]);
however, this tissue was more sensitive to the hyperglycemic state,
showing a signiﬁcant complex IV inhibition (up to 17%) as early as
10 days of treatment [F(2,6)=5.99; Pb0.05] (Fig. 2B). A different
mitochondrial metabolic proﬁle was observed for liver and kidney
tissues. The liver showed a signiﬁcant reduction in the activities of
complexes I and II of the respiratory chain after 30 days of
hyperglycemia (up to 45% and 34% of inhibition, respectively);
however, INS treatment only rescued from complex II inhibition and
provoked a marked increase in complex IV activity (73% of increment
compared to controls) (complex I: [F(2,20)=5.22; Pb0.05]; complex II:
[F(2,19)=88.24; Pb0.001]; complex IV: [F(2,6)=25.83; Pb0.001])
(Fig. 2C). In addition, ten days of hyperglycemia elicited increased
liver complex II activity that was prevented by the hormone
replacement (59% of increment compared to controls) [F(2,9)=6.90;
Pb0.05] (Fig. 2C). Neither the short- nor the long-term hyperglycemicstate modiﬁed the activities of the mitochondrial complexes in the
kidney. However, the INS treatment provoked marked increased
mitochondrial activities (up to 36%, 346% and 35% of increment,
respectively) (complex I: [F(2,17)=6.62; Pb0.01]; complex II: [F(2,20)=
131.14; Pb0.001]; complex IV: [F(2,6)=19.13; Pb0.01]) (Fig. 2D).
3.3. Effect of INS administration on DNA oxidation in skeletal muscle
from adult STZ-administered Wistar rats
Fig. 3 shows the effect of INS administration on DNA oxidation in
skeletal muscle from adult STZ-administered Wistar rats. The chronic
hyperglycemia (30 days) induced by STZ administration provoked
marked DNA oxidation (up to 1650% of increment), an effect that was
abolished by INS therapy [F(2,38)=16.84; Pb0.001].
3.4. In vitro effect of methylglyoxal (MG)-induced oxidized albumin
(MG-BSAlow and MG-BSAhigh) on respiratory chain complex activities in
mitochondrial preparations from skeletal muscle and hepatic tissues
Fig. 4A shows the characterization of BSA derivatives after MG
exposure. It can be observed that MG treatment reduced the content of
free BSA amino acid residues (up to 71% of reduction; Figure AI);
induced the formation of Maillard compounds (up to 2046% of
increment; Figure AII); increased the content of BSA carbonyl groups
(up to 4339% of increment; Figure AIII), and increased the oxidation of
Fig. 2. Effect of 10 and 30 days of insulin (INS; 1.5 UI Novolin®N insulin twice/day) administration on the activities of the complexes I, II and IV of the respiratory chain in skeletal muscle (AI–III), cardiac muscle (BI–III), liver (CI–III) and
kidney (DI–III) from adult streptozotocin (STZ)-administeredWistar rats. Data represent mean±standard deviation (3 to 9 animals/group). *Pb0.05; ** Pb0.01; *** Pb0.001, compared to controls. #Pb0.05; ##Pb0.01; ###Pb0.001, compared
to STZ group (one-way ANOVA followed by the Duncan multiple range test).
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Fig. 3. Effect of 30 days of insulin (INS; 1.5 UI Novolin®N insulin twice/day) administration on DNA oxidation in skeletal muscle from adult streptozotocin (STZ)-administeredWistar
rats. DNA oxidation were identiﬁed as described in Material and methods. For relative immunocontent quantiﬁcation, total pixels intensity was determined and data was expressed
as average of optical density (O.D.). *** Pb0.001, compared to controls. (One way ANOVA followed by the Duncan multiple range test). A, Control; B, STZ; C, STZ+INS.
1466 A.P. Remor et al. / Biochimica et Biophysica Acta 1812 (2011) 1460–1471amino acid residues that reacts with the Folin reagent in the protein
determination by the Lowry method (up to 19% of reduction; Figure
AIV). This MG-oxidized BSA was used for the following in vitro
experiments. Fig. 4B shows that 3 h exposure to MG-BSA (oxidized by
high MG concentrations; 100 mM; MG-BSAhigh) elicited a signiﬁcant
inhibition on complexes I–III and II activities (up to 76% and 85% of
inhibition, respectively) in adult rat skeletal muscle mitochondrial
suspensions (complexes I–III [F(6,14)=23.91; Pb0.001]; complex II
[F(6,14)=18.66; Pb0.001]). The inhibition elicited by 1 mg/mL MG-
BSAhigh was similar to the effect induced by the classic complex I
inhibitor, rotenone (10 μM); however, the effect on complex II activity
was 2-fold more severe than the inhibitor nitroproprionic acid (1 mM).
A similar inhibition rate was observed for these mitochondrial
complexes after exposing (3 h) hepatic mitochondrial preparations to
MG-BSAhigh (Fig. 4C); however, this tissuewasmore resistant to theAGE
inhibitory effect comparing to skeletal muscle (complex I up to 36% and
complex II up to 76.5% of inhibition) (complexes I–III [F(6,14)=18.82;
Pb0.001]; complex II [F(6,14)=13.56; Pb0.001]). Mitochondrial prepa-
rations treated with MG andMG-AGE at shorter periods of incubations,
15 min and 1 h, did not modify these activities (data not shown).
3.5. Short and long-term in vitro effect of methylglyoxal (MG) and
MG-induced oxidized albumin (MG-BSAlow and MG-BSAhigh)
on mitochondrial oxidative stress in primary rat skin ﬁbroblasts
Fig. 5A shows that 3 h exposure to 0.1 and 1 mg/mL MG-BSAhigh
elicited a signiﬁcant reduction in mitochondrial function as indicatedFig. 4. Characterization of bovine serum albumin (BSA) derivatives induced by methylglyo
complex activities in mitochondrial preparations from skeletal and liver tissues (B and C). Su
to MG-BSA for 3 h. Data represent mean±standard deviation (3 experiments/group). Contro
16.0, complex II: 3.70±0.50, and complex: IV 61.7±22.0; control values for liver complex
bovine serum albumin. MG-BSAhigh=BSA oxidized by high (100 mM) MG concentrations. M
*** Pb0.001, compared to controls. For further details about MG-BSA synthesis see Materiaby the ratio between MTT reduction (activities of dehydrogenases)
and DCF oxidation (content of reactive species) [F(3,8)=20.25;
Pb0.001]. In addition, it can be observed that a longer MG-BSA
exposure (24 h; Fig. 5B) provoked mitochondrial oxidative stress at
concentrations, as low as, 0.1 mg/mL of MG-BSAlow, with the higher
effect at 1 mg/mLMG-BSAhigh (up to 36.5% of oxidative stress-induced
reduction in mitochondrial function) (MG-BSAlow: [F(3,8)=12.40;
Pb0.01]; MG-BSAhigh: [F(3,8)=10.32; Pb0.01]). Furthermore, MG
exposure also provoked a signiﬁcant reduction in mitochondrial
function as seen by the marked reduction in the MTT reduction/
DCF oxidation ratio (up to 36.5% for 3 h and 24 h treatments) (3 h
[F(2,6)=199.80; Pb0.001]; 24 h [F(2,6)=101.21; Pb0.001]).
3.6. Long-term in vitro effect of MG-induced oxidized albumin
(MG-BSAlow and MG-BSAhigh) on mitochondrial respiration in
primary rat skin ﬁbroblasts
Fig. 6A shows that exposing skin ﬁbroblasts to 1 mg/mL MG-
BSAlow or 1 mg/mL MG-BSAhigh during 24 h provoked a signiﬁcant
inhibition of the electron transfer activity stimulated by FCCP (5.6 μM)
(up to 43% and 49% of inhibition for MG-BSAlow and MG-BSAhigh,
comparing to BSA) [F(3,8)=22.63; Pb0.001] (Fig. 6A). Respiration
without the addition of substrates (routine respiration) showed a
slight and non-signiﬁcant inhibition, which was clearly ampliﬁed by
using the FCCP strategy (Fig. 6B). The treatment with inhibitors did
not alter the oxygen consumption when skin ﬁbroblasts were treated
with MG-BSA. One-day treatment of skin ﬁbroblasts with lower (0.01xal (MG) exposure (MG-BSA) (A), and in vitro effect of MG-BSA on respiratory chain
spensions of mitochondria from skeletal muscle (B) and hepatic tissue (C) were exposed
l values (nmol .min−1 .mg protein−1) for skeletal muscle complexes I–III activity: 173±
es I–III activity: 186±16.3, complex II: 1.17±0.70 and complex IV: 151±33.0). BSA:
G-BSAlow=albumin oxidized by low (1 mM) MG concentrations. * Pb0.05; ** Pb0.01;
l and methods (one-way ANOVA followed by the Duncan multiple range test).
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Fig. 5. Short (A) and long-term (B) in vitro effect of methylglyoxal (MG) and methylglyoxal-induced oxidized albumin (MG-BSA) on mitochondrial oxidative stress in primary rat
skin ﬁbroblasts. Mitochondrial oxidative stress was estimated as the ratio betweenMTT reduction (activities of dehydrogenases) and DCF oxidation (content of reactive species) (see
Material and methods for further details). Data represent mean±standard deviation (3 experiments/group). MG: methylglyoxal. BSA: bovine serum albumin. MG-BSAhigh=BSA
oxidized by high (100 mM) MG concentrations. MG-BSAlow=albumin oxidized by low (1 mM) MG concentrations. *Pb0.05; ** Pb0.01; *** Pb0.001, compared to controls. (One-
way ANOVA followed by the Duncan multiple range test).
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modify any respiratory parameters (data not shown).
3.7. Effect of accumulating human plasma AGEs on mitochondrial
activity in rat skin ﬁbroblasts
Fig. 7A to C shows that plasma AGE content was signiﬁcantly
increased in hyperglycemic plasma from diabetic patients [t(10)=
3.26; Pb0. 01]. In addition, rat skin ﬁbroblasts treated with diluted
human plasma (1:4) for 24 h signiﬁcantly elicited MTT reduction
inhibition (up to 29% of inhibition; [t(19)=6.68; Pb0. 001]).
4. Discussion
Diabetes mellitus is a major metabolic disorder in which oxidative
stress and free radical production have been implicated through
several lines of evidence, and much of the long-term pathology of DM
appears to occur as a consequence of the persistent hyperglycemic
condition. Four major processes are thought to interplay and promote
the micro- and macrovascular changes characteristic of the DM
condition, namely the formation, auto-oxidation, and interaction with
cell receptors of AGEs; activation of various isoforms of protein
kinase C; induction of the polyol pathway; and increasing hexosamine
pathway ﬂux (for a review see [15]). The association of these
processes with oxidative stress has been linked for some time with
various sources proposed for the underlying production of reactive
oxygen species (ROS) [43,44]; moreover, it has been suggested that
increased mitochondrial superoxide overproduction during hyper-
glycemia might contribute to the onset, progression and pathological
consequences of DM [45,46].
4.1. Persistent hyperglycemia results in peripheral tissue-speciﬁc
patterns of energy metabolism deﬁcit possibly due to protein oxidation
It is known that mitochondrial complexes I and III are the major
sites of ROS generation under physiological conditions [47,48], and an
overt ROS production is observed when these redox centers are
blocked or their content is reduced [49,50]. Moreover, complex I is the
rate-limiting enzyme in oxidative phosphorylation (OXPHOS) [51].
Therefore, anymodiﬁcation of the function of this complex could have
a direct impact on the overall energy state of the cell. In line with this,
our study showed a severe impairment of energy metabolism in
peripheral tissues of hyperglycemic rats. Complex I, II and IV activities
in skeletal and cardiac muscles were signiﬁcantly reduced after30 days of hyperglycemia. Furthermore, the heart was found to be the
most sensitive tissue to the diabetic condition, since the energy
metabolism was impaired after 10 days of the hyperglycemic
condition. Different mitochondrial metabolic oxidative proﬁles were
observed in liver and kidney tissues from STZ-exposed animals. In the
liver there was a signiﬁcant reduction in the activities of complexes I
and II of the respiratory chain after 30 days of hyperglycemia, and a
marked increase in complex II activity after 10 days of hyperglycemia,
while in the kidneys there was no change in the OXPHOS system in
STZ animals.
This differential tissue vulnerability to hyperglycemia could be
related to early and persistent high levels of glucose or MG inducing
epigenetic changes as previously reported, e.g. increased expression of
NF-κB p65 subunit promoter [52] or reduced levels of mRNA for the
peroxisome proliferator-activated receptor γ co-activator 1α (PGC-
1α) [53]. In line with this, PGC-1α is able to up-regulate nuclear genes
that are required for mitochondrial biogenesis, including the OXPHOS
genes [54], and it has been proposed that this factor sets the speciﬁc
aerobic oxidative capacity for cardiac tissue [55]. On the other hand,
PGC-1α expression has been reported to be reduced in human
diabetes [53]; therefore, the deﬁciency in PGC-1α in hyperglycemic
conditions could result in a different pattern of changes in energy
metabolism mainly as a result of the metabolic properties and
mitochondrial content of the tissues, as shown here. In agreement
with this, it is known that PGC-1α expression is induced by AMP-
dependent kinase (AMPK) activation [56], while a deﬁciency in the
activity of this enzyme has been hypothesized to occur for this cell
energy sensor under diabetic conditions [57].
On the other hand, the overexpression of NF-κB (a free radical-
sensitive transcription factor), which has been demonstrated by El-
Osta and co-workers, in both cultured human aortic endothelial cells
and in non-diabetic mice [52], would aid in reducing the OXPHOS
activities by eliciting a downstream persistent oxidative stress
cascade that would ﬁnally converge to inhibit mitochondrial function.
Here, it was observed that this experimental model of chronic
hyperglycemia results in oxidative damage showed by the severe
DNA oxidation in skeletal muscle (Fig. 3), a tissue highly dependent
on mitochondrial energetics. This is also in agreement with a large
body of reports in the literature demonstrating systemic oxidative
stress in STZ-induced hyperglycemic animals [58–60].
The observed reduction in OXPHOS enzyme activities in the heart
after short and longer periods of hyperglycemia would lead to a
situation of pseudo-hypoxia, where the diabetic heart is not able to
utilize oxygen properly; however, in these circumstances there is no
Fig. 6. Long-term in vitro effect of methylglyoxal (MG)-induced oxidized albumin
(MG-BSA) on mitochondrial respiration (A), and stepwise titration carbonyl cyanide
p-triﬂuoromethoxyphenylhydrazone (FCCP) curve (B) in primary rat skin ﬁbroblasts.
The mitochondrial oxygen consumption under routine respiration, oligomycin, FCCP
and rotenone plus antimycin A conditions were assessed as indicated in Material and
methods. Data represent mean±standard deviation (3 experiments/group). MG-
BSAhigh=BSA oxidized by high (100 mM) MG concentrations. MG-BSAlow=albumin
oxidized by low (1 mM) MG concentrations. ** Pb0.01; *** Pb0.001, compared to
BSA (1 mg/mL) (one-way ANOVA followed by the Duncan multiple range test).
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is also unable to produce energy anaerobically, and the inadequate
oxygen consumption would lead to enhanced free radical production,
with the tissue therefore suffering from marked impairment in
oxidative metabolism. Consequently, therapies designed to improve
mitochondrial biogenesis/function would protect the diabetic failing
heart.
The different patterns of hyperglycemia-induced changes in
OXPHOS in the STZ-affected tissues analyzed here could also be
related to the cellular MG concentration, which may be due partly toFig. 7. Levels of glucose and advanced glycosylated end products in human diabetic plasm
dehydrogenases) was assessed in primary rat skin ﬁbroblasts (C). Data represent mean±s
Material and methods for further details). Hyper: Diabetic hyperglycemic plasmas; Controls
*** Pb0.001, compared to controls (Student'st test for unpaired samples).speciﬁc expression of the glyoxalase system, the main MG detoxifying
pathway, together with molecules such as glutathione, polyamines,
carnosine, creatine, and pyridoxamine, which normally exhibit
protective carbonyl-scavenging activity towards glycating com-
pounds, avoiding, therefore, the formation of AGEs [61]. In agreement
with this, we observed amarked reduction in complexes I and II of the
respiratory chain in MG-BSA-exposed skeletal muscle and liver
mitochondria from non-treated rats. Furthermore, mitochondrial
oxidative stress was induced by both MG-BSA and MG, under short
and longer periods of incubation, and this conditions impaired
mitochondrial physiology (cell respiration), since oxygen consump-
tion was signiﬁcantly inhibited after the MG-BSA treatment in skin
ﬁbroblasts.
4.2. Differential insulin-induced effects on peripheral
hyperglycemia-related changes in mitochondrial bioenergetics
Insulin administration was effective in protecting against the
hyperglycemia-induced inhibition of mitochondrial OXPHOS en-
zymes, possibly due to its demonstrated capacity to modulate the
levels of mRNA for genes encoding the respiratory chain complexes.
Insulin administration also increased OXPHOS activities in kidney
from STZ-treated animals, where the hyperglycemic state did not alter
electron transport activity. It has been reported that insulin exerts
part of its protective activity through activation of thephosphoinositide-
3-kinase (PI3K)-Akt pathway, which is known as a pro-survival
pathway [62]. Furthermore, Teshima and co-workers demonstrated
that insulin treatment is capable of down-regulatingPTEN(phosphatase
and tensin homologue deleted on chromosome 10) and phospho-PTEN
[63], a phosphatase that dephosphorylates the second messenger
produced by PI3K, thereby interrupting the downstream activation of
Akt [62]. On the other hand, PTEN could be up-regulated by increased
ROS production, mitochondrial dysfunction and/or persistent hyper-
glycemia [62,63]; therefore, it is possible that the severe changes in
energymetabolism observed in this study accompanying STZ exposure,
elicited bybothglucose toxicity and lackof insulinweremediated by the
inhibition of Akt signaling. Additionally, the long-term insulin exposure
increased the mitochondrial oxidative capacity of the tissue, although
this was observed with short-term hormone replacement only when
there was an STZ-inhibitory effect.
4.3. AGE-disrupted mitochondrial function
MG, MG-BSA and/or accumulating human plasma AGEs exposure
signiﬁcantly altered mitochondrial function in preparations of this
organelle from liver and skeletal muscle tissues, as well as, in skina (A and B). The effect of diabetic plasma exposure on MTT reduction (activities of
tandard deviation. Fibroblasts were exposed to diluted plasma (1/4) during 24 h (see
: Non-diabetic individuals. MTT control values: 0.23±0.02 (Optical density). ** Pb0.01;
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plexes I–III inhibition in liver and skeletal muscle mitochondria, while
complex IV remained without alterations. The lack of correlation with
the in vivo complex IV inhibition could bemainly related to the type of
experimental system used. Mitochondria isolated by differential
centrifugation are slightly contaminated with cytosol, only low
activity of nitric oxide synthase and therefore, lower levels of nitric
oxide, could be expected. In this context, AGEs are known to induce
nitric oxide formation, an endogenous inhibitor of complex IV;
however, this process would not be favored under these experimental
conditions [64].
On the other hand, these results agree with previous reports
indicating that AGE exposure (24 h) results in increased expression of
RAGE [65], and that AGE-RAGE interaction leads to ROS production
and loss of membrane mitochondrial potential [66], which would
subsequently lead to reduced ATP synthesis. Here, signiﬁcant
induction of mitochondrial oxidative stress (a decreased MTT
reduction:DCF oxidation ratio) was observed after exposing skin
ﬁbroblasts to oxidized albumin, with the effect being more pro-
nounced when cells were treated for 24 h. In addition, the observed
AGE-induced inhibition of electron transport chain enzyme activities
in mitochondrial preparations was also reﬂected in the rate of oxygen
consumption in rat dermal ﬁbroblasts. Fibroblast mitochondrial
function was also compromised by the human plasma accumulating
AGEs (Fig. 7B), which signiﬁcantly diminished the activity of
the mitochondrial dehydrogenases that reduced the MTT (Fig. 7C).
These results are in agreement with those from Phielix and co-
workers, demonstrating reduced mitochondrial respiratory capacity
(31%) in muscle ﬁbers from diabetic individuals [67]. Therefore, it
appears that the reduced mitochondrial activity in peripheral tissues
from STZ rats was mediated, in part, by hyperglycemia-induced AGE
formation.
4.4. Conclusions
Here we demonstrated that hyperglycemia results in tissue-
speciﬁc patterns of energy deﬁciency and that early and continuous
insulin therapy is necessary to maintain proper mitochondrial
oxidative metabolism via mechanisms that may determine the rate
of mitochondrial oxygen consumption and, therefore, ATP synthesis.
Moreover, hyperglycemia predisposed tissue to AGE formation and
AGE-induced mitochondrial oxidative stress, which might not only
damage mitochondria themselves, but also impair energetics by
inhibiting the rate of electron transfer. Thus, insulin replacement
appears to have an essential role in the maintenance of mitochondrial
homeostasis under diabetic conditions, particularly in the heart, the
peripheral tissue in which energetics relies primarily on mitochon-
drial oxidative metabolism.
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